Analyst Reco. Cano Health, Inc.

Equities

JWS

US13781Y2028

Market Closed - OTC Markets Other stock markets 15:54:08 2024-04-26 EDT			5-day change	1st Jan Change
0.2708 ^USD	-20.31%		+4.15%	-95.39%

04-22	First Amended Joint Reorganization and Disclosure Statement Plan Filed by Cano Health, Inc.	CI
04-15	Motion for De Minimis Asset Sale Approved for Cano Health, Inc.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Powell, the paper tiger	02-05
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	02-05	MT
UBS Downgrades Cano Health to Sell From Neutral, Adjusts Price Target to $3.75 From $12	11-17	MT
UBS Adjusts Cano Health Price Target to $12 From $150, Maintains Neutral Rating	11-07	MT
Credit Suisse Cuts Cano Health's Price Target to $0.50 From $2.50, Keeps Neutral Rating	23-08-14	MT
Cano Health Shares Slump as Citigroup, Jefferies Cut Stock Rating Following Q2 Results	23-08-11	MT
Truist Securities Starts Coverage on Cano Health with Hold Rating	23-08-11	MT
Jefferies Downgrades Cano Health to Hold From Buy	23-08-11	MT
Citigroup Downgrades Cano Health to Neutral From Buy, Adjusts Price Target to $0.80 From $4	23-08-11	MT
UBS Adjusts Cano Health Price Target to $1.50 From $1, Maintains Neutral Rating	23-06-21	MT
UBS Adjusts Cano Health Price Target to $1 From $1.25, Maintains Neutral Rating	23-05-09	MT
UBS Downgrades Cano Health to Neutral From Buy, Adjusts Price Target to $1.25 From $12	23-01-06	MT
Wolfe Research Downgrades Cano Health to Peer Perform From Outperform, Cuts Price Target to $2 From $7	23-01-05	MT
BofA Securities Reinstates Cano Health at Underperform With $1.50 Price Target	22-12-13	MT
Credit Suisse Trims Cano Health's Price Target to $4 From $5, Notes Lowered Guidance on Revenue Shortfall; Keeps Neutral Rating	22-11-28	MT
Citigroup Trims Price Target on Cano Health to $5 From $7, Maintains Buy Rating	22-11-16	MT
Cowen Downgrades Cano Health to Market Perform From Outperform, Lowers Price Target to $3 From $10	22-11-10	MT
Raymond James Downgrades Cano Health to Market Perform From Outperform	22-11-10	MT
Credit Suisse Downgrades Cano Health to Neutral From Outperform, Lowers PT to $5 From $10; Says Funding Environment Remains Challenged	22-10-27	MT
UBS Adjusts Cano Health Price Target to $12 From $14, Maintains Buy Rating	22-09-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cano Health, Inc.

Equities

JWS

US13781Y2028

Analyst Reco.

Filters